149 related articles for article (PubMed ID: 30770183)
1. Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting μ-opioid receptor antagonist.
Watari R; Matsuda A; Ohnishi S; Hasegawa H
Drug Metab Pharmacokinet; 2019 Apr; 34(2):126-133. PubMed ID: 30770183
[TBL] [Abstract][Full Text] [Related]
2. Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets.
Kanemasa T; Matsuzaki T; Koike K; Hasegawa M; Suzuki T
Life Sci; 2020 Sep; 257():118048. PubMed ID: 32622946
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Profile of Naldemedine, a Peripherally Acting
Kanemasa T; Koike K; Takase K; Arai T; Nakamura A; Morioka Y; Hasegawa M
J Pharmacol Exp Ther; 2020 Jun; 373(3):438-444. PubMed ID: 32169839
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation.
Kanemasa T; Koike K; Arai T; Ono H; Horita N; Chiba H; Nakamura A; Morioka Y; Kihara T; Hasegawa M
Neurogastroenterol Motil; 2019 May; 31(5):e13563. PubMed ID: 30821019
[TBL] [Abstract][Full Text] [Related]
5. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
6. Discovery of naldemedine: A potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects.
Inagaki M; Kume M; Tamura Y; Hara S; Goto Y; Haga N; Hasegawa T; Nakamura T; Koike K; Oonishi S; Kanemasa T; Kai H
Bioorg Med Chem Lett; 2019 Jan; 29(1):73-77. PubMed ID: 30446313
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the Peripheral μ-Opioid Receptor in Tramadol-Induced Constipation in Rodents.
Yasufuku K; Koike K; Kobayashi M; Chiba H; Kitaura M; Takenouchi S; Hasegawa M; Morioka Y; Mishima H; Suzuki T; Fujita M
Biol Pharm Bull; 2021; 44(11):1746-1751. PubMed ID: 34719650
[TBL] [Abstract][Full Text] [Related]
9. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
10. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
Takagi Y; Osawa G; Kato Y; Ikezawa E; Kobayashi C; Aruga E
BMC Gastroenterol; 2020 Jan; 20(1):25. PubMed ID: 32005157
[TBL] [Abstract][Full Text] [Related]
11. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine.
Fukumura K; Yamada T; Yokota T; Kawasaki A
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):162-174. PubMed ID: 30977959
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
Song X; Wang D; Qu X; Dong N; Teng S
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
[TBL] [Abstract][Full Text] [Related]
13. Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects.
Ohnishi S; Fukumura K; Kubota R; Wajima T
Xenobiotica; 2019 Sep; 49(9):1044-1053. PubMed ID: 30351180
[TBL] [Abstract][Full Text] [Related]
14. Naldemedine: Peripherally Acting Opioid Receptor Antagonist for Treating Opioid-induced Adverse Effects.
Inagaki M; Kanemasa T; Yokota T
Curr Top Med Chem; 2020; 20(31):2830-2842. PubMed ID: 32648846
[TBL] [Abstract][Full Text] [Related]
15. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
16. Naldemedine: A Review in Opioid-Induced Constipation.
Blair HA
Drugs; 2019 Jul; 79(11):1241-1247. PubMed ID: 31267482
[TBL] [Abstract][Full Text] [Related]
17. Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.
Mitra P; Venitz J; Yuan Y; Zhang Y; Gerk PM
Drug Metab Dispos; 2011 Sep; 39(9):1589-96. PubMed ID: 21685245
[TBL] [Abstract][Full Text] [Related]
18. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
Wang T; Agarwal S; Elmquist WF
J Pharmacol Exp Ther; 2012 May; 341(2):386-95. PubMed ID: 22323823
[TBL] [Abstract][Full Text] [Related]
19. The Impact of P-Glycoprotein on Opioid Analgesics: What's the Real Meaning in Pain Management and Palliative Care?
Coluzzi F; Scerpa MS; Rocco M; Fornasari D
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430602
[TBL] [Abstract][Full Text] [Related]
20. Involvement of P-glycoprotein and multidrug resistance associated protein 1 in the transport of tanshinone IIB, a primary active diterpenoid quinone from the roots of Salvia miltiorrhiza, across the blood-brain barrier.
Zhou ZW; Chen X; Liang J; Yu XY; Wen JY; Zhou SF
Drug Metab Lett; 2007 Aug; 1(3):205-17. PubMed ID: 19356045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
